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ABSTRACT: Here we report the synthesis of nanoparticles based on a conjugated oligomer which is synthesized through Heck-
coupling of divinylﬂuorene and dibromobenzothiodiazole monomers. These water dispersible nanoparticles emit in the region of
red tailing to the near-infrared region of the spectrum with high ﬂuorescent quantum yield and brightness. The nanoparticles
were found to be stable in water for a prolonged time without forming any aggregates and could carry camptothecin, an
anticancer drug with high loading eﬃciency. MTT cell viability studies performed with breast cancer cell lines showed that half-
maximal inhibitory concentration (IC50) values of nanoparticles for MCF7 and MDA-MB-231 were 44.7 μM and 24.8 μM,
respectively. In order to further decrease the cytotoxicity and increase the stability of nanoparticles, amine groups were disguised
by capping with cucurbit[7]uril (CB7). Drug release studies showed that drugs were released at low pH (at 5.0) faster than
physiological pH (7.4) conﬁrming the pH-responsive nature of the nanoparticles. On the other hand, CB7-capped drug-loaded
nanoparticles regulated the release rate by providing slower release at pH 7.4 than the nanoparticles in the absence of CB7s. IC50
values for camptothecin in the presence of nanoparticles with or without CB7 were signiﬁcantly reduced in MCF7 and MDA-
MB-231 cells.
■ INTRODUCTION
Conjugated polymer nanoparticles (CPNs) are highly appealing
for various advanced applications such as in vivo imaging, cell
labeling, and delivery of therapeutic agents, as well as
nanophotonics, owing to their high quantum yields and molar
absorptivity, tunable properties, easy functionalization, photo-
stability, and so forth.1−7 To date, the use of CPNs has been
demonstrated successfully in cell imaging, oxygen sensing, drug
delivery, and nucleic acid delivery.8−16
When these nanostructures are judiciously designed, they can
be utilized in theranostic applications by combining more than
one functionality to deliver therapeutic and imaging agents.17−21
For the controlled delivery of therapeutic agents to the targets
the nanoparticles could also include responsive groups that will
respond to stimuli such as pH, oxidation−reduction, and
enzymes. However, in the literature, examples are scarce
regarding the multifunctional conjugated polymer nanoparticles
(CPNs) and even less with conjugated oligomer-based nano-
particles (CONs).22,23 Recently, Schenning et al. compared the
capabilities of conjugated polymer nanoparticles to self-
assembled oligomer-based nanoparticles in terms of their
ﬂuorescent quantum yields, stabilities, molar absorptivity,
guest-holding, and releasing.24 They demonstrated that oligomer
nanoparticles have higher ﬂuorescent quantum yields and
comparable stabilities and molar absorptivity, but they release
the guest faster than the conjugated polymer nanoparticles. Thus,
this feature should be considered for the further design of
oligomer-based nanoparticles for theranostic applications. CONs
also oﬀer some useful additional features compared to CPNs
such as having well-deﬁned molecular weight and easier
metabolism and excretion from body after delivery due to their
smaller size compared to large polymeric species.
In this context, here we developed a strategy to utilize
conjugated oligomer-based nanoparticles in controlled drug
delivery and cellular imaging by designing and synthesizing
nanoparticles which are pH-sensitive, emitting in the region of
red tailing to infrared. Most importantly, the cytotoxicity of the
nanoparticles could be reduced and the drug release rate could be
regulated by capping the nanoparticles with cucurbituril as
demonstrated in the selected breast cancer cell lines. Cucurbituril
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(CB) is a rigid macrocyle which is constructed from an acid
catalyzed condensation of glycoluril with formaldehyde.25−28 CB
homologues can vary as CB5, CB6, CB7, CB8, and CB10
depending on the number of glycoluril units which they contain.
Among the CB homologues, CB5 and CB7 have good solubility
in water. CB homologues have a hydrophobic cavity and two
identical hydrophilic portals; owing to these features, they have
high aﬃnity toward ammonium and metal ions and form host−
guest complexes with suitable organic molecules mainly through
ion−dipole and hydrophobic interactions. CB homologues have
been used extensively in the construction of supramolecular
structures and more recently as vehicles for drug delivery due to
their nontoxic nature.29−31
■ EXPERIMENTAL SECTION
Materials. All reagents were purchased from Sigma-Aldrich
Chemical Co. and were used as received. Morphological character-
ization was achieved by transmission electron microscopy (TEM, FEI
Tecnai G2 F30) and scanning electron microsocopy (SEM). The size of
the nanoparticles was measured by dynamic light scattering (DLS,
Zetasizer Nano-ZS). Measurements were carried out at 633 nm and the
laser, as the light source, was used at room temperature. The time-
dependent autocorrelation function of the scattered light intensity was
measured at an angle of 90°. The average particle diameter was
calculated by the Marquardt method. The DLS measurements were
usually repeated at least three times and the average values are reported.
For the optical characterization, a UV−vis spectrophotometer (Cary
UV−vis) and a ﬂuorescence spectrophotometer (Cary Eclipse
Fluorescent spectrophotometer) equipped with a xenon lamp as the
excitation source were used. For the structural characterization, nuclear
magnetic resonance (NMR, a Bruker Avance III 400 for 1H and a 100
MHz spectrometer for 13C) and FT-IR (Bruker TENSOR 27) spectra
were obtained. Mass spectra were obtained under high resolution
(HRMS, Agilent, Model: 7890A/5975C) and elemental analysis were
carried out by a CHNS/O elemental analyzer (Thermo Scientiﬁc,
Model: Flash 2000). Deionized water was used to prepare the
nanoparticles.
Synthesis of 9,9-Bis(3-bromopropyl)-2-vinyl-9H-ﬂuorene,
M2. 2-Bromo-9,9-bis(3-bromopropyl)-9H-ﬂuorene, M1,3,4 (700 mg,
1.43 mmol) and 2,6-ditertiary butyl phenol (4.54 mg, 0.022 mmol) were
placed in a 2-necked RB ﬂask and dried under vacuum for 30 min.
Degassed toluene (20 mL) was added to it, followed by tributyl vinyl tin
(1.72 mmol, 544 mg, 0.6 mL), and the mixture was stirred for a while to
dissolve the contents of the ﬂask completely. Then the reaction mixture
was subjected to three freeze−pump−thaw cycles to remove oxygen,
and PdCl2(PPh3)2 (0.022 mmol, 15.4 mg) was added under N2 ﬂow.
The reaction mixture was then reﬂuxed for 24 h while stirring. After
completion of the reaction, the solvent was removed by rotary
evaporator under reduced pressure. The crude product was puriﬁed
by column chromatography using cyclohexane/DCM (9:1) as eluent to
isolate the pure product as a pale yellow solid. Yield: 560 mg; 90%. IR:
(solid state, KBr); ν (cm−1) 3100, 3000, 2850, 1650, 1470. 1H NMR
(CDCl3, 400 MHz, 25 °C) δ ppm: 1.15 (m, 4H, −CH2), 2.18 (t, J = 5.2
Hz, 4H, −CH2), 3.14 (t, J = 7.3 Hz, 4H, −CH2), 5.30 (d, J = 5.4, 1H,
−CHCH2), 5.84 (d, J = 2.8 Hz, 1H, −CHCH2); 6.80 (dd, J = 4.1
Hz, 1H, −CHCH2), 7.38 (m, 5H, Ar-H), 7.59 (m, 2H, Ar-H). 13C
NMR (CDCl3, 100 MHz, 25 °C) δ ppm: 27.1, 38.7, 53.6, 113.6, 120.0,
120.4, 122.8, 125.9, 127.5, 127.6, 137.1, 140.7, 149.7, 149.1. Elemental
analysis: calcd.: C, 58.09; H, 5.11; Br, 36.80; observed: C, 57.75; H, 5.11;
Br, 37.14. Mass (m/z) M+ = 433.0, 432.0, 436.2, 437.0.
Synthesis of 3,3′-(2-Vinyl-9H-ﬂuorene-9,9-diyl)bis(N,N-dime-
thylpropan-1-amine), M3. 9,9-Bis(3-bromopropyl)-2-vinyl-9H-ﬂuo-
rene,M2, (550 mg, 1.27) was dissolved in 15 mL of dried and degassed
THF in a 2-necked ﬂask, and the resulting solution was cooled down to
−78 °C and then 2M solution of dimethyl amine in THF (16.5 mmol, 8
mL) was added. Then, the reaction mixture was allowed to warm up to
room temperature and kept 24 h while stirring. After completion of the
reaction, the solvent and excess dimethyl amine were removed by rotary
evaporator, and the crude product was puriﬁed by column
chromatography using cyclohexane/DCM (7:3) mixture as eluent to
isolate the pure product as a pale yellow waxy solid. Yield: 418 mg, 91%.
1H NMR (CDCl3, 400 MHz, 25 °C) δ ppm: 0.75 (m, 4H, −CH2), 2.02
(m, 20H,−CH2 and−CH3), 5.25 (d, J = 5.2Hz, 1H,−CHCH2), 5.78
(d, J = 2.8 Hz, 1H, −CHCH2), 6.80 (dd, J = 4.0 Hz, 1H, −CH
CH2), 7.35 (m, 5H, Ar-H), 7.66 (m, 2H, Ar-H).
13C NMR (CDCl3, 100
MHz, 25 °C) δ ppm: 22.0, 37.8, 45.3, 54.6, 59.8, 113.0, 119.8, 120.4,
121.1, 122.8, 125.4, 126.1, 127.6, 130.1, 136.6, 140.2, 140.8, 149.7, 150.8,
152.4. IR (solid state, KBr), ν (cm−1): 3100, 1470, 3000, 1700, 2800,
1250. Elemental analysis calc. for C25H34N2·H2O: C, 78.91; H, 9.53; N,
7.36; O, 4.20; observed: C, 78.72; H, 9.61; N, 7.22. Mass (m/z) M+ =
363.28, 364.28.
Synthesis of Oligomer, 3,3′,3″,3‴-{[(1E,1′E)-2,1,3-benzothia-
diazole-4,7-diylbis(ethene-2,1-diyl)]-bis(9H-ﬂuorene-9,9,2-
triyl)}-tetrakis(N,N-dimethylpropan-1-amine). 4,7-Dibromo-
2,1,3-benzothiadiazole (322 mg, 1.10 mmol) and 3,3′-(2-vinyl-9H-
ﬂuorene-9,9-diyl)bis(N,N-dimethylpropan-1-amine), M3, (788 mg,
2.25 mmol) were placed in a 2-necked RB and dried under vacuum
for 30min. Then, degassed DMF (10mL) was added to it and stirred for
a while to dissolve the contents completely. An aqueous solution of
K2CO3 (5.5 mmol, 756 mg in 10 mL H2O) was added to the reaction
mixture. Then, the reaction mixture was subjected to 3 freeze−thaw−
pump cycles to remove oxygen completely. A catalytic amount of
Pd(OAc)2 (25.3 mg, 0.113 mmol) and Pd(PPh3)4 (26 mg, 0.023 mmol)
were added to it and the reaction mixture was heated to 90 °C for 24 h
while stirring under N2. After completion of the reaction, the solvent was
evaporated under reduced pressure and the crude product was extracted
by chloroform. Then, the solvent was evaporated and the resulting
residue was washed with cyclohexane to get a brown-colored sticky solid
which was further dissolved in THF and precipitated into coldMeOH to
yield a brownish sticky solid. Yield: 621 mg; 80%. IR (solid state, KBr) ν
(cm−1): 3100, 3000, 2850, 1650, 1470, 1240. 1H NMR (CDCl3, 400
MHz, 25 °C) δ ppm: 0.90 (m, 8H, CH2), 2.01 (m, 40H, −CH2 and
−CH3), 7.02 (d, J = 7 Hz, 4H, −CHCH), 7.41 (m, 6H, Ar-H), 7.70
(m, 10H, Ar-H). 13C (CDCl3,100 MHz, 25 °C) δ ppm: 22.0, 37.8, 45.2,
54.7, 59.7, 120.1, 121.1, 123.8, 125.5, 126.4, 127.1, 129.4, 133.8, 136.7,
140.8, 150.5, 150.7, 154.0. IR (solid state, KBr) ν (cm−1): 3100, 3000,
2850, 1650, 1470, 1240. Elemental analysis: calcd.: C, 78.45; H, 8.00; N,
9.80; S, 3.74; observed: C, 78.49; H, 8.21; N, 9.99; S, 3.31. Mass (m/z)
M+ = 857.51, 858.52, 859.53, 860.53, 861.53.
Nanoparticle Preparation. For preparation of nanoparticles of
oligomer, a stock solution of oligomer in THF (10 mg/mL) was
prepared before dilution with THF to get diﬀerent concentrations. One
milliliter of oligomer solution was injected into 20 mL of deionized
water under sonication. After the nanoparticle preparation THF was
removed from the dispersion by rotary evaporator under reduced
pressure. Then the nanoparticles were characterized by zeta sizer, SEM,
and TEM.
CB7-Capped Nanoparticles. To prepare CB7-capped NPs, we
mixed the aqueous solution of CB7 (by taking into consideration the
number of amine groups on the oligomer) with preprepared NPs. The
mixture was stirred gently and dialyzed using a 14 kDa MWCO
regenerated cellulose membrane for about 5 h against water to remove
uncomplexed CB7.
Synthesis of Drug Loaded Nanoparticles. In a typical procedure
to prepare drug loaded NP with a drug to oligomer ratio of 1:25 (w/w),
oligomer (4.0 mg, 4.66 × 10−3 mmol) was dissolved in 1 mL THF.
Camptothecin, CPT, (160 μg, 0.46 × 10−3 mmol) was dissolved in 320
μL THF. Then these two solutions were well dissolved by sonication for
10 min. The resulting solution was injected rapidly into 20 mL of
deionized water while sonicating, and sonication was continued for 30
min. THF was removed under reduced pressure, and the nanoparticle
dispersion was concentrated to 10 mL and dialyzed against 100 mL
deionized water using a 14 kDa MWCO regenerated cellulose
membrane for 24 h to remove any remaining unloaded CPT. Tween
20 (0.2% v/v) was added to dialysate to solubilize the free CPT. UV−vis
absorbance spectrum (λmax = 366 nm) of the dialysates were recorded to
determine the concentration of CPT. Samples of known concentration
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of CPT dissolved in water containing Tween 20 (0.2%,v/v) were used to
obtain a calibration curve of CPT.
In Vitro Drug Release Studies. Concentrated (5 mL) drug
encapsulatedNP dispersion wasmixed with 5mL of phosphate (pH 7.4)
or acetate (pH 5.0) buﬀer for neutral or acidic medium release,
respectively. Phosphate buﬀer (10 mM, 100 mL, pH = 7.4) or acetic
buﬀer (10 mM, 100 mL, pH = 5) containing 0.2% Tween 20 was used as
the release medium. Drug encapsulated NP dispersion mixed with
phosphate or acetate buﬀer transferred into a cellulose tubular
membrane with a molecular weight cutoﬀ 14 kDa. These were placed
in a beaker containing phosphate or acetate buﬀer medium, respectively,
and shaken at 60 rpm and 37 °C in an incubator. Two milliliters of
aliquot was taken from dialysate at diﬀerent time intervals. At each time,
equal amount of fresh PBS or acetate buﬀer was added to the dialysate
beaker to keep the dialysis conditions constant. The release mediumwas
completely replaced by fresh buﬀer solution at speciﬁc time intervals to
keep diﬀerent concentration gradients inside and outside the tubular
membrane.
MTT Cell Viability Assay. Breast cancer cell lines (MCF7 and
MDA-MB-231; ATCC) were cultured in 10% FBS at 37 °C with 5%
CO2. For cell viability assays, 2 × 10
3 cells were seeded in 96-well tissue
culture plates, and the next day cells were treated with diﬀerent
concentrations of Dulbecco’s Modiﬁed Eagle Medium (DMEM;
control), NP, CPT, CB, NP+CB, CPT+NP, CPT+CB+NP, and
DMSO (Supporting Information Table S2), each with four replicas.
After 72 h, culture media was removed and 10 μL ﬁltered 12 μMMTT
stock solution (Sigma-Aldrich) was added to 100 μL fresh medium in
each well. After 4 h the formazan crystals were dissolved in SDS solution
(0.3 M in 0.01 M HCl) and maintained in a 37 °C incubator for 18 h.
Color absorbance was measured using a microplate reader (uQuant,
Biotek) at a wavelength of 570 nm. Results were analyzed upon
normalization with respective DMEM control replicas.
Statistical Analysis. Diﬀerences in MTT relative cell viability
(normalized to DMEM control group) were analyzed for each dose in
each cell line separately using one-way ANOVAs followed by multiple
comparisons (Tukey’s at α = 0.05; Matlab). IC50 values of diﬀerent
formulations in breast cancer cell lines were calculated based on four-
parameter polynomial model (Graphpad).
Microscopy Experiments. Breast cancer cell lines, MCF7 and
MDA-MB-231, were cultured on 22× 22mm2 coverslips in 6-well tissue
culture plates at a density of 2 × 105 per well in DMEM/low glucose
(HyClone). The next day, cells were treated with 1 μMofNP or 1 μM/4
μMofNP+CB to compare with a no-treatment control group. After 72 h
cells were washed in PBS, ﬁxed 10 min in 4% paraformaldehyde, and
permeabilized in 0.1% Triton X-100. They were then incubated with
phalloidin (Alexa Fluor 488, Molecular Probes) for 40 min at room
temperature. Nuclei were stained with DAPI solution for 10min at room
temperature. After washings in PBS, coverslips were mounted on slides.
Images were captured using ﬂuorescent microscope (Axio Imager A1,
Zeiss) with 40× and 100× objectives. Moreover, to assess whether 24 h
treatment with NP and NP+CB was eﬀective for internalization of
nanoparticles in the absence as well as the presence of camptothecin
(0.03 μM), we performed experiments with MCF7 cells seeded at a
density of 5 × 105 in 6-well plates onto coverslips for three experimental
groups in duplicate, namely, only DMEM control, 0.5 μM NP, and NP
+CB (0.5 μM and 2 μM, respectively). After 24 h of treatment and
ﬁxation with 4% PFA, staining with DAPI was performed as described
previously. The experiment was repeated for MCF7 cells seeded at a
density of 2× 105 and treated for 72 h with drug loadedNP andNP+CB.
Images were captured using the 100× objective (Axio Imager A1, Zeiss).
■ RESULTS AND DISCUSSION
Oligomer, namely, 3,3′,3″,3‴-{[(1E,1′E)-2,1,3-benzothiadia-
zole-4,7-diylbis(ethene-2,1-diyl)]-bis(9H-ﬂuorene-9,9,2-triyl)}-
tetrakis(N,N-dimethylpropan-1-amine) was synthesized accord-
ing to Scheme 1. Brieﬂy, the reaction of 2-bromoﬂuorene with
1,3-dibromopropane in the presence of aqueous solution of
Scheme 1. Synthetic Route to Oligomer, 3,3′,3″,3‴-{[(1E,1′E)-2,1,3-Benzothiadiazole-4,7-diylbis(ethene-2,1-diyl)]-bis(9H-
ﬂuorene-9,9,2-triyl)}-tetrakis(N,N-dimethylpropan-1-amine)a
a(a) 1,3-Dibromopropane, aq. NaOH (50%, w/w), tetra-butyl ammonium bromide (TBAB), 80 °C, 1 h, 64%;3,4 (b) tributyl vinyltin,
Pd(Cl2)(PPh3)2, 2,6-di-tert-butyl phenol, toluene, 100 °C, 24 h, 90%; (c) dimethyl amine, THF, 0 °C−RT, 24 h, 91%; (d) aq. K2CO3, Pd(OAc)2,
Pd(PPh3)4, DMF, 90 °C, 24 h, 80%.
Figure 1. 1H NMR (CDCl3, 400 MHz, 25 °C) spectrum of oligomer.
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NaOH aﬀorded 2-bromo-9,9-bis(3-bromopropyl)-9H-ﬂuorene
(M1).3,4 The reaction of M1 with tributylvinyltin in toluene in
the presence of palladium catalyst gave 9,9-bis(3-bromo-propyl)-
2-vinyl-9H-ﬂourene, M2. Then, the compound M2 was reacted
with dimethyl amine to yield 3,3′-(2-vinyl-9H-ﬂourene-9,9-diyl)-
bis(N,N-dimethylpropane-1-amine), M3. Oligomer was synthe-
sized by the Heck coupling of 3 with 4,7-dibromo-2,1,3-
benzothiadiazole and puriﬁed by the precipitation of its THF
solution in cold methanol. It was characterized by spectroscopic
techniques (FT-IR, 1H NMR, 13C NMR) including elemental
analysis and mass spectrometer. Figure 1 shows the 1H NMR
spectrum of oligomer which conﬁrms its expected structure. The
oligomer exhibits good solubility in chloroform, THF,
acetonitrile, and DMF but not in methanol, ethanol, and water.
Synthesis of Nanoparticles and Investigation of Their
Stabilities. Oligomer contains a large hydrophobic backbone
(divinyl ﬂuorene and benzothiodiazole) and side chains with
hydrophilic amine groups owing to the structural features these
self-assembled nanoparticles could form in water. In order to
investigate the eﬀect of oligomer concentration on the
nanoparticle formation and optimize the sizes of the nano-
particles, oligomer solution in THF with varying concentrations
of 1, 2, 3, 4, and 5mg/mL were selected to prepare nanoparticles.
The hydrodynamic diameter of the prepared nanoparticles
(NPs) was determined by dynamic light scattering (DLS)
measurements. For each concentration, the experiments were
repeated at least 3 times by keeping the same preparation
conditions. It was observed that, by increasing oligomer
concentration, the size of NPs increased gradually ranging
from 48.97± 0.34 nm for 1mg/mL to 90.75± 0.96 nm for 5mg/
mL. The zeta potential values were found to be ranging from +20
± 1.4 to +57.2 ± 0.6 for concentrations between 1 mg/mL to 5
mg/mL. This positive value of zeta potential was due to the
amine functional group in the pendant chain of oligomer
indicating the formation of stable nanoparticle dispersion caused
by repulsion between the nanoparticles. SEM and TEM images
showed a good agreement with the DLS data with a particle size
of ∼50 nm. Supporting Information Table S1 and Figures S11,
S12 show the average zeta size, polydispersity index (PDI), and
zeta potential of NPs for diﬀerent concentration of oligomer
solution. For further investigation we selected the oligomer
concentration as 4 mg/mL with the NP size of 57.0 ± 0.69 nm
with PDI of 0.185± 0.031 and zeta potential of 52.5± 1.3. Figure
2a,b,c shows the SEM, TEM images and DLS histogram,
respectively, of oligomer with concentration of 4 mg/mL THF.
The stability of NPs over time was investigated in water and
phosphate buﬀer (pH 7.4). During this period, the NPs were
highly stable and no precipitation occurred. On the other hand,
nanoparticles precipitated in acetate buﬀer (pH 5.0) within a
short time period of ∼5 h, indicating the protonation of amine
groups on the nanoparticles; once the amine groups are
protonated, nanoparticles start to swell leading to the
disassembly of nanoparticles. The stability of NPs was also
investigated in diﬀerent biological media including milk protein,
bovine serum albumin, DMEM, and human serum albumin. For
these experiments, 1 mL of NP dispersion was mixed with an
equal amount of medium and shaken at 60 rpm at 37 °C for 24 h.
As can be seen from Figure 3a, NPs were highly stable in DMEM
maintaining their initial size. Although in BSA and milk no
precipitate formation was observed, the sizes of nanoparticles
Figure 2. (a) SEM (scale 1 μm), (b) TEM (scale 50 nm) images and dynamic light scattering (DLS) histogram of oligomer nanoparticles.
Figure 3. Stability of oligomer nanoparticles (a) in water and phosphate buﬀer (pH 7.4) and (b) in BSA, Milk, DMEM, and blood serum.
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slightly increased (Figure 3b). On the other hand, NPs
precipitated in human serum albumin during the incubation
possibly due to the nonspeciﬁc interaction of amine groups of
nanoparticles with blood serum proteins causing the aggregate
formation.
In order to circumvent the nonspeciﬁc interactions of amine
groups with proteins and increase the stability of NPs in the
biological media, we developed a simple strategy by taking
advantage of the high binding aﬃnity of amine groups toward
cucurbiturils26−30 (CBs) (Scheme 2). CB7 was selected in this
study due its good water solubility. To prepare CB7-capped NPs,
we mixed the aqueous solution of CB7 (by taking into
consideration the number of amine groups on the oligomer)
with preprepared NPs. The mixture was stirred gently and
dialyzed brieﬂy against water to remove uncomplexed CB7.
DLS measurement showed that the sizes of CB7-capped
nanoparticles have increased only by ∼5 nm to get 62.13 ± 2.11
nm (Supporting Information Figure S16). The SEM data also
support the result obtained from DLS experiment (Supporting
Information Figure S16-c). However, the zeta potential of CB7
capped oligomer NPs were decreased to +24.4 ± 2.31 mV from
its original value (without CB addition) of +52.5 ± 1.3 mV
indicating the complexation between CB7 and amine groups
(Supporting Information Figure S17).
Furthermore, CB-capped NPs have remained stable in water
and in phosphate buﬀer (pH 7.4) solutions over a period of 35
days, but precipitated in the acetate buﬀer as observed with the
nanoparticles without CB7s. We have also found that CB-capped
NPs were highly stable without any precipitation in blood serum
proteins over 24 h incubation period; this clearly indicates that
CB7s have been preventing the interaction of nanoparticles with
proteins by capping amine groups.
To gain insight into the location of CB7 on the NPs, we have
conducted 1H NMR experiments. For these experiments,
samples were prepared by freeze−drying the aqueous dispersions
of NPs with CB7 and without CB7. In both cases, the freeze−
dried NPs redispersed well in water and D2O. Only a slight
increase was observed in their sizes according to DLS
measurements. Although the peaks in the 1H NMR spectra of
NPs are quite broad due to self-assembly of oligomer chains, we
can still diﬀerentiate the diﬀerences in the spectra of CB-capped
NPs and NPs without CBs (Supporting Information Figure
S15). In the 1HNMR spectrum of CB-capped NPs, the peaks for
the protons of pendant groups of oligomer are downﬁeld shifted
comparing to the peaks in the spectrum of NPs in the absent of
CB7. Especially, the downﬁeld-shifting is more signiﬁcant
(approx. 0.2 ppm) in the case of dimethylamine protons,
indicating that pendant groups are not encapsulated by CB7 but
CB7 is in close proximity to the pendant group and there is an
interaction between the nitrogen of the dimethyl amine and the
carbonyl groups of CB7; because of this interaction the protons
of dimethylamine groups were deshielded and the signal due to
these protons shifted downﬁeld.
Optical Properties of Oligomer and Its Nanoparticles. The
optical properties of oligomer in THF, chloroform, and the
nanoparticle dispersion in water were studied by UV−visible and
ﬂuorescence spectroscopy (Figure 4) and tabulated in Table 1.
UV−vis absorption wavelengths of oligomer in chloroform,
THF, and DMF were not signiﬁcantly diﬀerent (λmax at 473, 466,
and 473 nm, respectively), while for the nanoparticle dispersion
in water, UV−vis absorption wavelength (λmax) appeared at 455
nm exhibiting an 11−18 nm blue-shift compared to the
aforementioned solutions of oligomer. Fluorescence spectra
showed that the emission of oligomer in chloroform, THF, and
DMF and NPs in water were 595, 605, 602, and 615 nm,
respectively. Nanoparticles in water exhibited a red shift
compared to its solution in organic solvents.
The changes in the optical properties can be explained by both
inter- and intrachain interaction, as well as the solvent
polarity.12,20 Fluorescent quantum yields of oligomer in
chloroform, THF, DMF, and nanoparticles of oligomer in
water were calculated as 51.3%, 46.8%, 36.1%, and 15.6%,
respectively.
Drug Loading Study of Oligomer Nanoparticles. To
investigate the drug loading and drug release properties of
nanoparticles, camptothecin (CPT) was used as the model
Scheme 2. Overview of the Preparation of CB-Capped Drug-Loaded Nanoparticles and pH-Triggered Drug ReleaseMechanism of
the Nanoparticles
Biomacromolecules Article
dx.doi.org/10.1021/bm500839j | Biomacromolecules 2014, 15, 3366−33743370
anticancer drug. The amount of loaded drug was calculated by
measuring the drug concentrations before and after being loaded
by nanoparticles. The absorption of dialysate was recorded for
λmax of CPT at 366 nm and the concentration of loaded CPT was
computed using a standard calibration plot that was prepared
under identical conditions for known concentrations of CPT.
The entrapment eﬃciency (EE) and drug loading eﬃciency
(DLE) were calculated according to the following eqs 1 and 2.
= ×EE% Amount of loaded drug/total amount of drug 100
(1)
=
+ ×
DLE% Amount of loaded drug/(amount of loaded drug
amount of oligomer) 100 (2)
Four sets of drug loaded NPs were prepared with drug to
oligomer ratios of 1:25 (w/w), 17.2:1 (w/w), 12.5:1 (w/w), and
6.25:1 (w/w) to investigate the entrapment and drug loading
eﬃciency of nanoparticles. After encapsulation of drug, the
nanoparticles retained their spherical shape with a small
increment of ∼5−10 nm in the average hydrodynamic size.
The drug loading content (EE) increased and reached a
maximum value 95.8 ± 0.7% with an increase of feed amount
ratio of CPT to oligomer at 17.2:1 (Figure 5). The entrapment
ratio was dropped to 40.0 ± 1.1 by further increase of feed
amount of CPT to oligomer by 6.25:1. Figure 6 showed that the
entrapment eﬃciency and drug loading eﬃciency of nano-
particles varied with diﬀerent drug to oligomer ratios.
The drug loading eﬃciency increased by augmentations on the
drug to oligomer ratio and reached an optimum value of 5.86 ±
0.04% for 17.2:1 (Figure 6). Further increase of the feeding
amount of drug did not greatly aﬀect the drug loading
eﬃciencies. By considering both the entrapment and drug
loading eﬃciencies, the ratio of drug to oligomer was ﬁxed at
17.2:1 for further studies. Hydrophobic eﬀect and π−π
interactions between the aromatic moiety of oligomer and the
aromatic rings of CPT might be a possible driving force for the
encapsulation of drug molecules to the nanoparticles.21
In VitroDrug Release Study of OligomerNanoparticles.
The in vitro drug release studies of oligomer nanoparticles were
carried out in two pH media, viz., in phosphate buﬀer (pH 7.4)
and in acetate buﬀer (pH 5.0) as described in the Experimental
Section. For drug release studies the drug to oligomer ratio was
Figure 4.UV−vis absorption and emission spectra of oligomer in THF,
chloroform, and oligomer NPs in water.
Table 1. Optical Properties of Oligomer in Diﬀerent Solvents
and Dispersion of Oligomer Nanoparticles in Water
solvent
λabs
(nm)
λem
(nm)
Φfa
(%)
εb (cm−1
M−1)
brightnessc
(cm−1M−1)
CHCl3 473 595 51.3 25728 13198
THF 466 605 46.8 27598 12916
DMF 473 602 36.1 44097 15917
Water 455 615 15.6 19548 3050
aFluorescent quantum yields are calculated using Rhodamine B in
ethanol as standard (Φf: 98%). bMolar absorptivity. cProduct of molar
absorptivity and ﬂuorescent quantum yield.
Figure 5. (a) SEM (scale 1 μm), (b) TEM (scale 100 nm), and (c) DLS histogram of CPT loaded oligomer nanoparticles.
Figure 6. Entrapment eﬃciency and drug loading eﬃciency of
nanoparticles with diﬀerent drug to oligomer ratios.
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kept at 17.2:1 as optimized in drug loading studies. Release of the
CPT from the nanoparticles in acetate buﬀer was relatively faster
than that in the phosphate buﬀer (Figure 7). About 97% of the
CPT was released from the nanoparticle at pH 5.0 in the ﬁrst 12
h, but only 46% of CPT was released in a neutral environment in
the same time period. CPT release from the nanoparticles in
phosphate buﬀer was completed (∼98%) only in 84 h. The faster
release of CPT from the nanoparticles in an acidic environment
can be explained by the disassembly of nanoparticles by the
positive charge formation at amino group (to ammonium ion) in
the presence of an acidic environment as shown in Scheme 2.
Further, drug release studies of CB7-capped NPs were
conducted using the same drug to oligomer ratio. Scheme 2
illustrates the preparation of CB-capped drug loaded nano-
particles and the pH-triggered drug release mechanism of these
nanoparticles. Release of CPT at pH 5.0 from CB7-capped NPs
was found to be almost similar to that in the absence of CB.
However, in the case of phosphate buﬀer (pH 7.4), the release of
drug was much slower; in the ﬁrst 12 h, only 7.5% and around 60
h 50% of the CPT were released. The CPT release from the CB
capped nanoparticles was completed (∼98%) by 144 h, at a rate
slower than that obtained from CB uncapped nanoparticles.
The results clearly show that the presence of CBs provides a
sustained drug release in the physiological pH but enables fast
release at low pH, which can be found in the tumor micro
environments.32,33
In Vitro Cell Assays.MTT assays have been frequently used
to test the cytotoxic activity of nanoparticles in breast cancer cell
lines.34,35 In our study, MCF7 and MDA-MB-231 breast cancer
cells treated with NP exhibited signiﬁcant reductions in relative
cell viability dose-dependently (Figure 8). MDA-MD-231 cells
were more resistant to NP treatment at lower concentrations
0.125−0.5 μM (0.332−0.934; log10 μM) but exhibited similar
reductions in cell viability as obtained for MCF7 cells. At the
given concentrations a subpopulation of cells remained alive in
both cell types (Figure 8). IC50 values of NP, calculated based on
four-parameter polynomial model, were 44.7 μM and 24.8 μM
for MCF7 and MDA-MB-231, respectively. Viabilities in CB
alone and NP+CB treatments were similar and comparable to
DMEM control group. These results demonstrated that NP
driven toxicity could be reversed in NP+CB complex suggesting
that toxicity of NPwas reduced in the presence of CB at the given
1:4 (NP:CB) ratio.
Increased eﬃciency in drug delivery is another functionality
nanoparticles can oﬀer. Drug delivery capacity of NP and NP
+CB treatments was measured in MCF7 and MDA-MB-231
breast cancer cell lines in response to CPT in a dose-dependent
manner (Figure 9). Both cell lines exhibited reduced cell viability
when given together with NP or NP+CPT in comparison to
CPT treatment alone. DMSO treatment had no signiﬁcant eﬀect
on cell viability when normalized to DMEM untreated controls.
IC50 values for treatments, calculated using a four-parameter
polynomial ﬁt on logarithmically transformed CPT concen-
trations, showed that CPT+NP and CPT+NP+CB complexes
resulted in signiﬁcant reductions in cell viability when compared
with that obtained by treatment with CPT alone (Figure 10).
One-way ANOVA of the relative cell viability performed for each
cell line at each dose followed by multiple test comparisons
revealed signiﬁcant pairwise diﬀerences between CPT+NP/CPT
+NP+CB and CPT alone (Figure 9).
MCF7 and MDA-MB-231 breast cancer cell lines have been
eﬀective models to estimate toxicity as well as drug delivery
capacity of nanoparticles. For example, emodin (EMO) loaded
solid lipid nanoparticles (SLN) exhibited higher cytotoxicity with
respect to EMO solution using MTT tests in MCF7 and MDA-
MB-231 cells.35 In our study, MCF7 andMDA-MB-231 cells had
IC50 values for camptothecin (CPT) at 0.541 and 0.615 μM,
respectively. In both cell lines, complex formation of NP with CB
(NP+CB) eﬀectively reduced IC50 values by 35% and 23%,
Figure 7. CPT release proﬁle of oligomer nanoparticle in phosphate
(pH 7.4) and acetate buﬀer (pH 5.0).
Figure 8. Relative cell viability (%) measurements obtained from MTT analyses at the given concentrations (log10, μM) of NP, CB, and NP+CB
treatments upon normalization with DMEM control group in MCF7 and MDA-MB-231 breast cancer cell lines (Supporting Information Table S2).
Experimental groups with signiﬁcant multiple pairwise test diﬀerences were indicated in comparison with NP group at p < 0.05.
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respectively, for MCF7 and MDA-MB-231. The dose dependent
cytotoxic eﬀect of NP/NP+CB encapsulating CPT was relatively
greater for MCF7 than for MDA-MB-231 (Figure 9).
Dual-ﬂuorescent staining in microscopy plays an important
role for obtaining insight into the location of nanoparticles taken
up in the cell. We used phalloidin cytoskeletal staining together
with nuclear DAPI staining in MCF7 and MDA-MB-231 breast
cancer cells to overlay with the images obtained for the NP and
NP+CB (Figure 10).
Merged images indicated that nanoparticles were relatively
enriched near the nuclear membrane and mostly located in
cytoplasm as diﬀused or relatively aggregated specks (as in the
case of MCF7 and MDA-MB-231, respectively; Figure 10)
raising the possibility of NPs being enriched in intracellular
compartments including endosomes and/or lysosomes. Similar
studies performed with other nanoparticle types indeed showed
that nanoparticles might be trapped in cytosolic vesicles upon
uptake.36 For example, distribution of quantum dots diﬀered
from phase to phase in a time dependent manner, and phase 3
was characterized by perinuclear vesicular enrichment of these
dots.36,37 Xiao et al. have suggested that the route taken by
quantum dots into the cell could be through endocytosis
followed with sequestration into early endosomes and then
targeting to late endosomes or lysosomes.38 pH values of early
endosomes (5.9−6.0) and lysosomes (4.0−5.5) vary, and thus
translocation of nanoparticles from one compartment to another
also might have an eﬀect on visibility of nanoparticles that exhibit
sensitivity to pH.38,39 The NP in the present study exhibited pH
sensitivity, and at low pH values NP had lower emission intensity
as we also studied the pH sensitivity of NPs by ﬂuorescence
spectroscopy (see SI for discussion and Figure S13). Therefore,
intracellular pH sensitivity and diﬀerential targeting of naiv̈e and
drug-loaded NP andNP+CB should be tested over time in future
studies by simultaneously tracing the particles for colocalization
with early endosomal and late endosomal/lysosomal markers.
Our ﬁndings also demonstrated that naive as well as
camptothecin-loaded NP and NP+CB were taken up by MCF7
cells as early as 24 h of exposure (SI, Figure S18). Naive NP upon
complexation with CB produced weaker signals in the cell at 72 h
(Figure 10) but not at 24 h (SI Figure S18). Florescent signals
from drug-loaded NP and NP+CB were detected densely in the
cytoplasm potentially due to reduced cytoplasmic volume, and at
times overlapped with the signal obtained from nuclear stain
DAPI at both 24 and 72 h time points (SI Figure S18).
Expectedly, drug loaded NP and NP+CB resulted in cytotoxicity
as evidenced by reduced cell number and nuclear size when
compared with DMEM control groups at 24 and 72 h treatments
(SI Figure S18). These results suggest that intracellular targeting,
metabolism, pH sensitivity, and intensity of NP and NP+CB
might be aﬀected by the batch of NP/NP+CB, absence/presence
of drugs in NP, as well as cell type and dose/time of the exposure.
Hence, future studies should focus on quantitative analysis of
diﬀerences in the uptake and intensity of ﬂuorescence signals
emitted by NP and NP+CB in a time and drug-dose dependent
Figure 9. Relative cell viability (%) measured by MTT in response to camptothecin (CPT) at the given concentrations (log10, μM) of DMSO control,
CPT alone, CPT+NP, and NP+CB+CPT treatments upon normalization with DMEM control groups in MCF7 and MDA-MB-231 breast cancer cell
lines (Supporting Information Table S2). IC50 values were calculated based on four-parametric polynomial ﬁt model separately for each treatment
group. Experimental groups with signiﬁcant multiple pairwise test diﬀerences were indicated in comparison with CPT group at p < 0.05.
Figure 10.MCF7 and MDA-MB-231 cells treated with NP and NP+CB complexes and compared with Control (DMEM) group. Nuclei were stained
with DAPI (blue; LP420) while phalloidin antibody was used for staining F-actin (green; FITC; LP515). Emission from nanoparticles was obtained
using LP590 red ﬁlter, and images from all three channels were overlaid (Axio Imager A1, Zeiss).
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manner using diﬀerential organelle markers and high resolution
microscopy.
■ CONCLUSION
In this paper we have demonstrated the use of red emitting
conjugated oligomer in the nanoparticle synthesis. These
conjugated oligomer-based self-luminescent, pH-responsive
nanoparticles could be used for controlled-drug delivery and in
vivo imaging owing to its red to far-red emission with high
quantum yield and brightness, which are highly sought after for
optical imaging.
MTT cell viability studies performed with breast cancer cell
lines for MCF7 and MDA-MB-231 clearly showed that the
presence of CBs reduced the cytotoxicity. The toxicity eﬀect
could be attributable to the presence of amine groups on the side
chains of oligomer. In order to decrease the cytotoxicity and
increase further the stability of nanoparticles, amine groups were
disguised by capping with CB7 as the partially protonated amines
could complex with the carbonyl groups of CBs. Moreover,
through CB-capping of nanoparticles, the drug-release rate could
be regulated.
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